UPDATE: Barrington Research Raises Price Target on Thoratec to $38

According to Barrington Research, Thoratec

price target is raised to $38. Barrington Research said that THOR reported strong Q4/11 results with revenue up 12% to $109.4 million versus $97.6 million in Q4/10. “We are reiterating our OUTPERFORM rating and raising our target from $36 to $38 based on the company's technology and clinical leadership in the large and growing HF market.” Thoratec closed on Friday at $34.19.